Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria-Reference-Cited by-同舟云学术

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Published:2022-09 Issue: Volume:173 Page:285-296
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Larkin James,Weber Jeffrey,Del Vecchio Michele,Gogas Helen^ORCID,Arance Ana M.,Dalle Stephane,Cowey C. Lance,Schenker Michael^ORCID,Grob Jean-Jacques,Chiarion-Sileni Vanna^ORCID,Márquez-Rodas Iván,Butler Marcus O.,Di Giacomo Anna Marie^ORCID,Middleton Mark R.^ORCID,De la Cruz-Merino Luis,Arenberger Petr,Atkinson Victoria,Hill Andrew,Fecher Leslie A.,Millward Michael,Khushalani Nikhil I.,Queirolo Paola^ORCID,Long Georgina V.^ORCID,Lobo Maurice,Askelson Margarita,Ascierto Paolo A.^ORCID,Mandalá Mario

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Adjuvant nivolumab versus ipilimumab in resected stage III of IV melanoma;Weber;N Engl J Med,2017

2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

3. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

5. Systemic therapy for melanoma: ASCO guideline;Seth;J Clin Oncol,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift;Frontiers in Immunology;2024-01-03

2. Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-11-07

3. Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL;Cancers;2023-09-30

4. Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma;European Journal of Medical Research;2023-09-16

5. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study;European Journal of Cancer;2023-09